This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): Tonapofylline, BG9928, CVT-124, BG9719, A1 Adenosine Receptor Antagonist
Description: BioMedTracker has separate drug profiles for the oral and intravenous formulations of Adentri. Please also see Adentri (intravenous).
ADENTRI (oral) is an A1 adenosine receptor antagonist.
In March 1997, Biogen licensed rights to develop adenosine A1 receptor inhibitors from CV Therapeutics. CV Therapeutics' original compound was known as CVT-124 (BG9719).
In January 2009, Astellas Pharma announced that it submitted a proposal to the Board of Directors of CV Therapeutics to acquire all outstanding common shares of CV Therapeutics for $16.00 per share in cash.
In March 2009, Gilead Sciences and CV Therapeutics announced the signing of a definitive agreement pursuant to which Gilead will acquire CV Therapeutics for $20.00 per share in cash through a tender offer and second step merger. The acquisition was completed in April 2009.
Partners: Gilead Sciences, Inc.
Adentri (oral) News
Additional information available to subscribers only: